"Toll-Like Receptor 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that binds unmethylated CPG CLUSTERS. It mediates cellular responses to bacterial pathogens by distinguishing between self and bacterial DNA.
| Descriptor ID |
D051217
|
| MeSH Number(s) |
D12.776.260.750 D12.776.543.750.705.910.500.900
|
| Concept/Terms |
Toll-Like Receptor 9- Toll-Like Receptor 9
- Toll Like Receptor 9
- TLR9 Receptor
- Receptor, TLR9
- TLR9 Protein
- CD289 Antigen
- Antigen, CD289
|
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 9".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 9".
This graph shows the total number of publications written about "Toll-Like Receptor 9" by people in this website by year, and whether "Toll-Like Receptor 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 2 | 5 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Toll-Like Receptor 9" by people in Profiles.
-
The RNA receptor RIG-I binding synthetic oligodeoxynucleotide promotes pneumonia survival. JCI Insight. 2024 Nov 08; 9(21).
-
Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nat Biomed Eng. 2024 May; 8(5):593-610.
-
TLR2, TLR3, TLR4, TLR9 and TLR11 expression on effector CD4+ T-cell subsets in Leishmania donovani infection. Exp Parasitol. 2023 Dec; 255:108645.
-
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022 12 01; 28(23):5079-5087.
-
Unique TLR9 Activation by Helicobacter pylori Depends on the cag T4SS, But Not on VirD2 Relaxases or VirD4 Coupling Proteins. Curr Microbiol. 2022 Mar 03; 79(4):121.
-
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
-
Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys. Brain. 2021 08 17; 144(7):2146-2165.
-
Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9. J Med Chem. 2021 07 08; 64(13):9279-9301.
-
Inducible Epithelial Resistance against Coronavirus Pneumonia in Mice. Am J Respir Cell Mol Biol. 2020 10; 63(4):540-541.
-
CpG postconditioning after reperfused myocardial infarction is associated with modulated inflammation, less apoptosis, and better left ventricular function. Am J Physiol Heart Circ Physiol. 2020 11 01; 319(5):H995-H1007.